The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

BACKGROUND: Clinically significant portal hypertension (CSPH) drives cirrhosis-related complications (i.e. hepatic decompensation). Impaired nitric oxide (NO) bioavailability promotes sinusoidal vasoconstriction, which is the initial pathomechanism of CSPH development. Activation of soluble guanylyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiberger, Thomas, Berzigotti, Annalisa, Trebicka, Jonel, Ertle, Judith, Gashaw, Isabella, Swallow, Ros, Tomisser, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123479/
https://www.ncbi.nlm.nih.gov/pubmed/37095557
http://dx.doi.org/10.1186/s13063-023-07291-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10123479/
https://www.ncbi.nlm.nih.gov/pubmed/37095557
http://dx.doi.org/10.1186/s13063-023-07291-3

Ejemplares similares